Despite the 2018 Farm Bill removing hemp — defined as cannabis and cannabis derivatives with very low concentrations (no more than 0.3% on a dry weight basis) of THC — from the definition of marijuana in the Controlled Substances Act, CBD products are still subject to the same laws and requirements as FDA-regulated products that contain any other substance.
Misleading, unproven, or false claims associated with CBD products may lead consumers to put off getting important medical care, such as proper diagnosis, treatment, and supportive care. For that reason, it’s important to talk to your doctor about the best way to treat diseases or conditions with available FDA-approved treatment options.
Potential harm, side effects and unknowns
Unlike the FDA-approved CBD drug product, unapproved CBD products, which could include cosmetics, foods, products marketed as dietary supplements, and any other product (other than Epidiolex) making therapeutic claims, have not been subject to FDA evaluation regarding whether they are effective to treat a particular disease or have other effects that may be claimed. In addition, they have not been evaluated by the FDA to determine what the proper dosage is, how they could interact with other drugs or foods, or whether they have dangerous side effects or other safety concerns.
The FDA is evaluating the regulatory frameworks that apply to certain cannabis-derived products that are intended for non-drug uses, including whether and/or how the FDA might consider updating its regulations, as well as whether potential legislation might be appropriate. The information we have underscores the need for further study and high quality, scientific information about the safety and potential uses of CBD.
The FDA’s top priority is to protect the public health. This priority includes making sure consumers know about products that put their health and safety at greatest risk, such as those claiming to prevent, diagnose, treat, mitigate, or cure serious diseases. For example, the agency has warned companies to stop selling CBD products they claim are intended to prevent, diagnose, treat, mitigate, or cure serious diseases such as cancer, Alzheimer’s disease, psychiatric disorders and diabetes. While we have focused on these types of products, we will continue to monitor the marketplace for any product that poses a risk to public health, including those with dangerous contaminants, those marketed to vulnerable populations, and products that otherwise put the public health at risk.
By Type, the market is segmented into Full-spectrum CBD, Broad-spectrum CBD, and CBD isolate. Trends regarding CBD isolates are expected to be boosted during the review period. Endocannabinoids are the purest form of cannabinoids as the are further refined to remove the phytocannabinoids, terpenes, other plant parts, and other cannabinoids. CBD isolates are tasteless and odorless and do not produce recreational subjective effects.
However, the availability of products in the CBD gummies market is limited, which restricts the growth of the CBD gummies industry. An increase in awareness of CBD gummies’ benefits can replace unhealthy confections with an increase in better health. The removal of THC has produced a positive influence on cannabis-derived products.
The market is divided into stores and non-stores. The non-store-based segment continues to drive the market, even over the past year. The number of CBD e-commerce sites has increased over the last year. The availability of wide range of product offerings at a reasonable price has helped move the online segment forward. When purchasing CBD products, customers are able to maintain their identity, which is also valued by the customers.
Top Companies involved in CBD Gummies Market are CHARLOTTE’S WEB (US), CV Sciences (US), Green Roads World (US), Medterra (US), Balanced Health Botanicals (US), Dixie Brands Inc (US), Medix Wellness LTD (US), Diamond CBD (US), Premium Jane (US) and CBDfx (US)
Major players of the market are
About Market Research Future:
CBD Plant Nutrients Market: Information by Type (Macronutrients and Micronutrients), Category (Organic and Conventional), Mode of Application (Drenching, Fertigation and Foliar) and Region (North America, Europe, Asia-Pacific and Rest of the World) – Forecast till 2027
The legalization of cannabis and the increase in the use of cannabis in the treatment of various diseases drive the CBD market’s growth. Apart from that, diverse uses of cannabis and consumers’ increased interest in cannabis edibles are the chief factors that drive the market. The increasing use of cannabis in the market has increased the demand for cannabis edibles. The growing popularity of CBD-containing products for medicinal and recreational purposes has led to the growth of the market in little more than a few years. Research from around the US has found that CBD can help with anxiety, pain, depression, and inflammation. CBD (cannabidiol) gummies are non-psychoactive, non-addictive, and non-intoxicating. They are tasteless and odor-free, which the consumers prefer. The legalization of industrial hemp for medicinal and recreational purposes across various states in the US will create new opportunities for investors in the CBD infused products market. Many CBD-oil product manufacturers have formed partnerships with other companies to further expand their market scope.